Sun, Apr 20, 2014, 12:39 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Google Inc. Message Board

dariodbest 32 posts  |  Last Activity: Apr 9, 2014 6:55 AM Member since: Mar 6, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • HEB)
    Last Trade: 0.50
    Trade Time: 9:04AM EDT
    Change: Up 0.09 (21.40%)
    Bid: 0.00 x 999,999

    Sentiment: Strong Buy

  • A lot of them very under value with good potential especially those in phase 3

    Sentiment: Strong Buy

  • Gdt ready, all the weak sold already!!

    Sentiment: Strong Buy

  • The data on the experimental immunotherapeutic included a re-examination post-hoc of the primary and secondary endpoints as a function of dichotomization of patient responses.

    Dichotomization of improvement in exercise performance from baseline at the =25% and =50% levels were analyzed on the Intent-to-Treat Population.
    For the ITT population a significantly greater percentage of rintatolimod patients (39%) vs. placebo patients (23%) improved ET (exercise tolerance) duration by =25% while 26% compared to 14% of rintatolimod vs. placebo patients, respectively, improved ET duration by =50%.
    A frequency distribution analysis of =25% improvement, 9 minutes cohort showed net improvement to be 18.3% for the rintatolimod cohort vs. 4.6% deterioration for placebo.
    A continuous responder analysis using 5% increments from =25% to =50% provided a robust clinical enhancement in ET effect in the rintatolimod cohort for the ITT population, as well as, for a subset of patients with baseline ET duration 9 minutes as compared to placebo.
    The Karnofsky Performance Score and Vitality quality of life secondary endpoints demonstrated similar clinically significant improvements for the rintatolimod cohort as a function of the same ET dichotomization. Rintatolimod was generally well-tolerated in this CFS/ME population.

    Sentiment: Strong Buy

  • The data on the experimental immunotherapeutic included a re-examination post-hoc of the primary and secondary endpoints as a function of dichotomization of patient responses.

    Dichotomization of improvement in exercise performance from baseline at the =25% and =50% levels were analyzed on the Intent-to-Treat Population.
    For the ITT population a significantly greater percentage of rintatolimod patients (39%) vs. placebo patients (23%) improved ET (exercise tolerance) duration by =25% while 26% compared to 14% of rintatolimod vs. placebo patients, respectively, improved ET duration by =50%.
    A frequency distribution analysis of =25% improvement, 9 minutes cohort showed net improvement to be 18.3% for the rintatolimod cohort vs. 4.6% deterioration for placebo.
    A continuous responder analysis using 5% increments from =25% to =50% provided a robust clinical enhancement in ET effect in the rintatolimod cohort for the ITT population, as well as, for a subset of patients with baseline ET duration 9 minutes as compared to placebo.
    The Karnofsky Performance Score and Vitality quality of life secondary endpoints demonstrated similar clinically significant improvements for the rintatolimod cohort as a function of the same ET dichotomization. Rintatolimod was generally well-tolerated in this CFS/ME population.

    Sentiment: Strong Buy

  • April awareness, HEB WILL pop to new high

    Sentiment: Strong Buy

  • California here we come.........AMPLIGIN is the key..Phase3 completed in CFS/ME....
    Ampligen Phase 2b ongoing in USA for HIV and Phase 3 Preperation in CHINA.
    Ampligen Preclinical for Avian Flu in Canada, USA, and Japan.

    Alferon N Injection for Hepatitis C PREP phase 3 in China
    Alferon N Injection Phase 2 Preparation (USA) for Multiple Sclerosis
    also Phase 2/3 Preparation - Investigator Sponsored (USA) for West Nile Virus
    Alferon LDO Phase I/II Ongoing (USA & Hong Kong) Antiviral Indications ...Phase 2 Preparation (Africa) for HIV

    The highlight of the presentation was the fact that “antibodies were detected against highly pathogenic influenza strains” in 70 percent of the subjects who were enrolled in the tests. Hemispherx Biopharma, Inc. (NYSE MKT:HEB) presentation was presented under the topic header, ”Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen(R)), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA .
    As part of the phase 1 and 2 trials, the vaccine FluMist(R) was administered via injections in addition to the company developed Ampligen(R). The study found that 92% of the administered patients were able to develop “specific IgA antibodies” against previously identified seasonal vaccine strainsthe amount of intranasal Ampligen(R) used in this study was as low as one eight thousandth (1/8,000) of the dose.” The drug firm also clarified that there was no additional adverse impacts what were observed or reported during the study, there by explaining the safety aspect of the study. ....... (These studies using the same 2 drugs show how this company is worth more IMHO ..

    This is going to be a GREAT week for HEB .. And there pipeline

    Sentiment: Strong Buy

  • monday heb can open over $1
    4.5 million shares traded today.

    Sentiment: Strong Buy

  • dariodbest by dariodbest Mar 21, 2014 12:58 PM Flag

    n Wednesday, shares in Hemispherx Biopharma Inc. edged 0.38% lower to finish the day at $0.40. The stock recorded a trading volume of 1.07 million shares as compared to a three months average volume of 3.14 million shares. The stock fluctuated between $0.39 and $0.41 during the session. Hemispherx Biopharma Inc.'s stocks have advanced 1.20% in the previous three trading sessions, 1.90% in the last one month, and 49.92% on YTD basis. The company's shares are trading above its 200-day moving average. Hemispherx Biopharma Inc.'s 50-day moving average of $0.40 is above the 200-day moving average of $0.28. Moreover, the stock is trading at the Relative Strength Index (RSI) of 49.48. Sign up today to read free research on HEB at:

    Sentiment: Strong Buy

  • Some one its loading up ,big can close over .43 tomorrow .565

    Sentiment: Strong Buy

  • dariodbest by dariodbest Mar 20, 2014 2:50 PM Flag

    Cfs.monday presentation will be intresting.and some one its loading up!!

    Sentiment: Strong Buy

  • WE ARE READY!!!

    Sentiment: Strong Buy

  • .55 PLUS TOMORROW

    What Causes CFS?

    CFS/FMS acts as a "circuit breaker," with the hypothalamus decreasing its function to protect the individual in the face of what is perceived to be an overwhelming stress (just like blowing a fuse/circuit breaker in a house). This center controls sleep, hormones, temperature, and blood flow/blood pressure/sweating. When you don't sleep deeply, your immune system also stops working properly and you'll be in pain. In addition, if your muscles do not have enough energy, they will get stuck in the shortened position and you will be in pain (think rigor mortis). This "energy crisis" can be caused by any of a number of infections, stresses, or injuries.

    Some of you had your illness caused by any of a number of infections. In this situation, you can often give the time that your illness began almost to the day. This is also the case in those of you who had an injury (sometimes very mild) that was enough to disrupt your sleep and trigger this process. In others the illness had a more gradual onset. This may have been associated with hormonal deficiencies (e.g., low thyroid, estrogen, testosterone, cortisone, etc.) despite normal blood tests. In others, it may be associated with chronic stress, antibiotic use with secondary yeast overgrowth, and/or nutritional deficiencies. Indeed, we have found well over 100 common causes of, and factors that contribute to, these syndromes.

    Understanding this helps us understand the symptom complex seen in CFS/fibromyalgia. Restoring energy production so that your hypothalamic circuit breaker turns back on and eliminating what blew your fuse in the first place also gives us a way to effectively treat you!

    Sentiment: Strong Buy

  • we can see .565 tomorrow

    Sentiment: Strong Buy

  • Reply to

    Phase 3 ummmm!!!

    by dariodbest Mar 19, 2014 8:41 AM
    dariodbest dariodbest Mar 19, 2014 9:28 AM Flag

    Don't think so. Article mentions current research

    Sentiment: Strong Buy

  • dariodbest by dariodbest Mar 19, 2014 8:41 AM Flag

    How many studies we have with ampligen on phase 3?

    Sentiment: Strong Buy

  • Loan for new fda facility completely paid off last October.

    Sentiment: Strong Buy

  • dariodbest by dariodbest Mar 10, 2014 3:59 PM Flag

    Very soon

    Sentiment: Strong Buy

  • dariodbest by dariodbest Mar 10, 2014 3:56 PM Flag

    Very soon.

    Sentiment: Strong Buy

GOOG
536.10-20.44(-3.67%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.